ClinicalTrials.gov
ClinicalTrials.gov Menu

The Sublimated Mare Milk Supplement's Effect on Gut Mucosal Lining After Antibiotics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03657836
Recruitment Status : Recruiting
First Posted : September 5, 2018
Last Update Posted : September 11, 2018
Sponsor:
Collaborators:
Eurasia Invest Ltd.
Ministry of Education and Science, Republic of Kazakhstan
Information provided by (Responsible Party):
Almagul Kushugulova, Nazarbayev University Medical Center

Brief Summary:
This clinical trial studies the effect of sublimated mare milk supplement on gut microbiome of patients with acute bronchitis.

Condition or disease Intervention/treatment Phase
Acute Bronchitis Dietary Supplement: Sublimated mare milk supplement Drug: Standard antibiotic therapy Not Applicable

Detailed Description:

Food has a significant effect on the health of the body, the relationship between diet and health actualizes the importance of expanding the research of functional products. In mare's milk contains about 40 biological components necessary for the human body: amino acids, fats, enzymes (lysozyme, amylase), microelements (calcium, sodium, potassium, phosphorus, iron, magnesium, copper, iodine, sulfur, cobalt, zinc, bromine) and vitamins (A, C, B1, B2, B6, B12, E, H, PP, beta-carotene, folic acid) in optimally balanced proportions.

A high percentage of nutrients, including vitamins, amino acids, contribute to immunomodulation, increasing the adaptogenic properties of the body. Valiev A demonstrated the effect of the essential fatty acids of mare's milk on immunocompetent cells and non-specific resistance after 6 weeks from the beginning of inclusion in the ration of mare's milk.

Secretory IgA is the main immunoglobulin of mare's milk. The homology of human secretory IgA and mare's was previously demonstrated by cross-reactions using human anti-IgA antiserum.

The mare's milk has a powerful detoxification effect, the mare's microflora neutralizes the effect of mutagens, possesses, replenishes with the necessary complex of nutrients and removes toxins from the body. The milk has a certain degree of antimicrobial effect in relation to opportunistic and pathogenic fungi, bacteria and viruses due to its own microflora.

The mare's milk is rich in active substances, natural enzymes that help regulate intestinal flora, limiting the growth of unwanted bacteria and increasing the growth of bifidobacteria and lactic acid bacteria.

In addition, the composition of mare's milk provided immunoglobulins A, M and G, which act as a marker of those microorganisms that can be pathogenic, which facilitates the protection task.

The high antimicrobial activity of mare's milk is associated with the lysozyme contained in it, immunoglobulins, lactoperoxidase and lactoferrin. Getting into the digestive tract lysozyme has a powerful normalizing effect on the composition of the microbial flora of the mouth and intestines. Lysozyme of breast milk is 100 times more active than lysozyme of cow's milk. It not only inhibits the growth of pathogenic flora, but also promotes the growth of bifidoflora in the intestines of infants.

In the framework of the project, methods for the restoration of the mucos layer of the intestine after antibiotic therapy will be developed. In order to develop the algorithm, preliminary studies will be made of changes in the structure of the intestinal microbiota after antibiotic therapy. Recruiting of patients with infectious / non-infectious pathology is supposed, clinical and laboratory examination, biomaterial sampling during antibiotic therapy, 1-5 days and 1-60 days after completion will be performed. Along with the study of microflora, local immunity studies will be carried out. To study the fundamental foundations, experimental studies will be carried out on laboratory animals. On the basis of the knowledge obtained, an algorithm for the restoration of the mucinous layer of the intestine after antibiotic therapy will be published in the form of methodological recommendations.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Effectiveness of the Sublimated Mare Milk Supplement in Protection of Gut Mucosal Lining During Antibiotic Treatment
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dietary supplement and antibiotics
Participants will take a supplement of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) once a day for 60 days accompanied with the standard antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
Dietary Supplement: Sublimated mare milk supplement
The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.

Drug: Standard antibiotic therapy
Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.

Antibiotics only
Participants will take the prescribed antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
Drug: Standard antibiotic therapy
Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.




Primary Outcome Measures :
  1. Changes in intestinal microbial composition [ Time Frame: Baseline, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 10, Day 15, Day 20, Day 25, Day 30, Day 35, Day 40, Day 45, Day 50, Day 55, Day 60 ]
    Rectal swabs will be taken for further analysis of DNA sequence with MiSeq Reporter PCR Amplicon.

  2. Changes in intestinal immune status biomarkers. [ Time Frame: Baseline, Day 60 ]
    Levels of immune markers (cytokines, secretory Immunoglobulin A, interleukins) will be assessed from stool samples.


Secondary Outcome Measures :
  1. Changes in weight of the patient [ Time Frame: Baseline, Day 60 ]
    Weight will be assessed according to percentile tables

  2. Defecation frequency [ Time Frame: Baseline, up to 60 days ]
    Defecation frequency based on patient's/parent's/guardian's reports over period of 60 days

  3. Changes in consistency of stool [ Time Frame: Baseline, Day 60 ]
    Consistency of stool will be evaluated according to Bristol scale with severe hard lumps and liquid stool being a severe constipation (Type 1) and severe diarrhea (Type 7) respectively.

  4. Changes in color of stool, [ Time Frame: Baseline, Day 60 ]
    Stool color changes will be assessed based on baseline and final visit (Day 60).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   4 Years to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients of both sexes aged 4-5 years
  • The voluntary informed consent of the parent to participate in the study
  • Established diagnosis of acute upper respiratory tract disease with prescription of antibacterial therapy
  • The duration of symptoms of acute upper respiratory tract disease no more than 72 hours
  • Lack of prescription of antibacterial drugs in the last 3 months

Exclusion Criteria:

  • Severe forms of acute infections
  • The presence in the history of taking probiotics and antibiotics for three months before admission to hospital
  • Presence in the anamnesis of chronic diseases of the digestive tract, and also of any surgeries on the digestive tract
  • The presence of severe concomitant diseases of the kidneys, liver, cardiovascular, respiratory and other body systems, cancer, mental and decompensated endocrine diseases, tuberculosis, HIV infection
  • Patient involvement in other clinical trials within the last 3 months
  • Lack of willingness of the patient to cooperate with the doctor-researcher

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03657836


Contacts
Contact: Almagul Kushugulova, MD, PhD +77777727813 umc.ct2018@gmail.com
Contact: Ayaulym Nurgozhina, MSc +77015351164 anurgozhina@nu.edu.kz

Locations
Kazakhstan
Nazarbayev University Medical Center Recruiting
Astana, Kazakhstan, 010000
Contact: Bakytgul Yermekbayeva, MD, PhD         
Sub-Investigator: Bakytgul Yermekbayeva, MD, PhD         
Sub-Investigator: Rashida Satybayeva, MD         
Sub-Investigator: Kairat Rysbekov, MD         
Sponsors and Collaborators
Nazarbayev University Medical Center
Eurasia Invest Ltd.
Ministry of Education and Science, Republic of Kazakhstan
Investigators
Principal Investigator: Almagul Kushugulova, MD, PhD National Laboratory Astana

Publications:
Responsible Party: Almagul Kushugulova, Head of the Laboratory of Human Microbiome and Longevity, Nazarbayev University Medical Center
ClinicalTrials.gov Identifier: NCT03657836     History of Changes
Other Study ID Numbers: AP05135073
First Posted: September 5, 2018    Key Record Dates
Last Update Posted: September 11, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Almagul Kushugulova, Nazarbayev University Medical Center:
Acute Bronchitis
Mare milk
Gut mucosa
Antibiotics

Additional relevant MeSH terms:
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Anti-Bacterial Agents
Ceftriaxone
Cefuroxime
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents